Navigation Links
NeurogesX Announces Preliminary Results from Second Phase 3 Clinical Trial in HIV-DSP
Date:2/27/2008

er studies and there was a trend in favor of treatment. We will continue to evaluate whether the cumulative clinical data from our clinical studies may be able to support evidence of efficacy in HIV-DSP."

The study, a multi-center, double-blind, controlled Phase 3 clinical trial in a total of 494 patients, was similar in design to the Company's previous successfully completed phase 3 study in HIV-DSP. Study C119 contained two treatment arms (30-minute and 60-minute arms) for both NGX-4010 and a control patch containing a low concentration of the same active ingredient as NGX- 4010. When looking at the individual treatment arms, the 30-minute group treated with NGX-4010 achieved a 26.1% reduction in pain from baseline compared to 19.1% for the control group (p=0.1) and the 60-minute group treated with NGX-4010 achieved a 32.8% reduction in pain from baseline compared to 30.1% for the control group (p=0.5). Secondary endpoints also did not achieve statistical significance.

Anthony DiTonno, Chief Executive Officer, commented, "We remain focused on our overall goal of achieving commercial launch of NGX-4010 in 2009. We are on track to file a new drug application (NDA) with the U.S. Food and Drug Administration (FDA) later this year in postherpetic neuralgia (PHN), and are continuing with the Marketing Authorization Application (MAA) under the centralized procedure in the Europe Union where our application for approval was accepted by the European Medicines Agency (EMEA) in September of last year. We expect to consult with both regulatory agencies in the coming weeks to discuss how the results of this most recently completed trial, when taken in the context of the entire clinical development record of NGX-4010, which has been studied in over 1,600 patients, may support gaining an approval broader than the potential PHN indication. "

NGX-4010 is a dermal patch containing capsaicin, a selective TRPV1 agonist, designed to manage peripheral neuropathic p
'/>"/>

SOURCE NeurogesX, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. NeurogesX Completes Enrollment in Confirmatory Phase 3 Clinical Trial for Painful HIV Distal Sensory Polyneuropathy
2. NeurogesX Completes Enrollment in Confirmatory Phase 3 Clinical Trial for Painful HIV Distal Sensory Polyneuropathy
3. NeurogesX Announces Positive Results from Second Phase 3 Clinical Trial in Postherpetic Neuralgia
4. EndoGastric Solutions(TM) Announces Results of EsophyX(TM) Multi-Center GERD Study
5. Dong-A PharmTech Co., Ltd. Announces Portal Hypertension Clinical Trial With Udenafil
6. MacuSight(TM) Announces Positive Preliminary Results From Phase 1 Study of Sirolimus in Wet Age-Related Macular Degeneration
7. InteKrin Therapeutics Announces Initiation of Phase 2b Study in Type 2 Diabetes with INT131
8. amfAR Announces Funding for HIV Services and Research Aimed at Men Who Have Sex With Men in Developing Countries
9. ATS Medical Announces Initial Clinical Results of Stand-Alone Atrial Fibrillation Procedures Using ATS CryoMaze Product Line
10. ISTA Pharmaceuticals Announces Physician-Sponsored Clinical Study of Xibrom(TM) Combination Therapy with Lucentis(R)
11. Accumetrics Announces $28.8 Million Financing and Initiation of Pivotal Clinical Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2013)... 2013 /PRNewswire-iReach/ -- World markets are constantly changing ... trends and events, companies now need a global ... industry is headed next, so that they can ... http://photos.prnewswire.com/prnh/20130522/CG19099 ) Global Information Inc ... GlobalData, offer decision makers and executives integrated business ...
(Date:5/22/2013)... , May 22, 2013  Viral hepatitis is an asymptomatic ... percent of those with hepatitis C are unaware they have ... and Awareness Day in the U.S. House of Representatives will ... Rayburn Foyer of the Rayburn House Office Building in ... Association for the Study of Liver Diseases ( AASLD ) ...
(Date:5/22/2013)... N.Y. , May 22, 2013  The Leukemia ... million to Valor Biotherapeutics, LLC, a joint venture ... pre-clinical development, manufacturing, and a Phase I clinical trial ... poor outcomes faced by many patients with indolent lymphomas ... Valor,s protein, IGN002, is a new ...
Breaking Medicine Technology:Adapt, React, Evolve: Staying Ahead in the Breast Cancer Gene Testing, Solar Energy, and Oil & Gas Markets with Reliable Analytics and Actionable Insights from GlobalData's 700 Market Analysts 2Adapt, React, Evolve: Staying Ahead in the Breast Cancer Gene Testing, Solar Energy, and Oil & Gas Markets with Reliable Analytics and Actionable Insights from GlobalData's 700 Market Analysts 3Adapt, React, Evolve: Staying Ahead in the Breast Cancer Gene Testing, Solar Energy, and Oil & Gas Markets with Reliable Analytics and Actionable Insights from GlobalData's 700 Market Analysts 4Hepatitis Awareness: Bringing Attention to a Silent Epidemic 2The Leukemia & Lymphoma Society, Valor Biotherapeutics and ImmunGene Create Partnership to Advance Novel Therapy for Non-Hodgkin Lymphoma Patients 2The Leukemia & Lymphoma Society, Valor Biotherapeutics and ImmunGene Create Partnership to Advance Novel Therapy for Non-Hodgkin Lymphoma Patients 3The Leukemia & Lymphoma Society, Valor Biotherapeutics and ImmunGene Create Partnership to Advance Novel Therapy for Non-Hodgkin Lymphoma Patients 4
... 2007 - Rexahn,Pharmaceuticals, Inc. (OTC BB:RXHN), a ... commercialization of,innovative treatments for cancer, central nervous ... needs, today announced,that Dr. John Marshall, Principal ... Company's lead cancer compound RX-0201 (Archexin),will present ...
... Clinical Trials for Organ Transplantation, HORSHOLM, Denmark, May ... I clinical results for,its transplantation product candidate, LCP-Tacro ... organ transplantation. , Today LifeCycle Pharma A/S (OMX:LCP) ... program of LCP-Tacro, a,proprietary, once-daily tacrolimus tablet. , ...
Cached Medicine Technology:LifeCycle Pharma Announces Positive Phase I Clinical Results for,its Transplantation Product Candidate, LCP-Tacro 2LifeCycle Pharma Announces Positive Phase I Clinical Results for,its Transplantation Product Candidate, LCP-Tacro 3
(Date:5/22/2013)... Boise, ID (PRWEB) May 22, 2013 ... us. This Memorial Day (May 27, 2013) Bodybuilding.com will be ... regardless of the amount. , “We are extremely grateful ... in the Armed Forces,” said Ryan DeLuca, CEO and founder ... nations heroes who have sacrificed so much. Hire Heroes USA ...
(Date:5/22/2013)... ARBORA University of Michigan study challenges previous research ... Baseball. , The study, a collaboration between researchers ... Florida, looks deeper into the controversial argument over ... strikes for pitchers of the same race. It ... said Jason Winfree, associate professor of sport management ...
(Date:5/22/2013)... 22, 2013 Award Presented at the ... press release here: http://bit.ly/13DkFfk , Merrill Corporation ... “Information Management Product/Service of the Year” at the 7th ... The Colony Hotel in Palm Beach, Florida. , ... room (VDR) solution that optimizes the due diligence ...
(Date:5/22/2013)... Space Girl Organics is excited to ... weekend's I Talk to Strangers Miracle Run/Walk . The ... Riverside Park in Cocoa, FL. The event aims to “create ... social movement. , As a sponsor, Space Girl Organics is ... the event. Additionally, they are providing bananas for runners and ...
(Date:5/22/2013)... Go Classy the Original Nudist Travel Agent and ... newest website http://www.Desire-Mexico.com . The seductively liberating couples ... have become the premier Nudist and Lifestyle Vacation destination. ... while allowing you to enjoy a deluxe all inclusive ... / Caribbean-Hideaways. He goes on to say "Desire Resorts ...
Breaking Medicine News(10 mins):Health News:In the Spirit of Memorial Day, Bodybuilding.com is Donating a Portion of Their Sales to Hire Heroes 2Health News:U-M study challenges notion that umpires call more strikes for pitchers of same race 2Health News:Merrill DataSite New Press Release: Merrill DataSite® Virtual Data Room Honored as “Information Management Product/Service of the Year” 2Health News:Merrill DataSite New Press Release: Merrill DataSite® Virtual Data Room Honored as “Information Management Product/Service of the Year” 3Health News:Space Girl Organics to Sponsor May 25 Miracle Run/Walk 2Health News:Go Classy Tours Announces the Launch of Their Newest Website for Desire Resorts Located in Mexico Clothing Optional/Aunaturel Resorts a Lovers Paradise 2
... genetically modified maize developed by U.S. biotech giant Monsanto, ... developed liver and kidney problems. ,Greenpeace said ... the journal Archives of Environmental Contamination and Technology showed ... showed "signs of toxicity" in the liver and kidneys. ...
... an eye each allegedly due to medical neglect after ... were to blame because they had not taken adequate ... cataract operation camp at the government hospital at Bhabanipatna ... operated upon, all above 60 years. ,Six ...
... The Dr Reddy's Laboratories (DRL), a leading Indian pharmaceutical firm, ... all-in-one polypill// for heart problems on 250 patients in the ... put it in the market by the end of this ... for dilating arteries, relaxing heart muscles, removing excess water and ...
... casein proteins reduced the development of eczema by 33 ... ,"The 3-year results of this large-scale, prospective, randomized, ... for [atopic dermatitis] AD but not for early asthma ... high risk for allergic diseases," wrote lead author Andrea ...
... in Britain indicates that the salt intake of the Britishers has ... Health experts opine that cardiac arrests and strokes can be prevented ... the report, there is a decrease of salt consumption from 9.5g ... cut down their salt intake from 11g to 10.2g while in ...
... London have shown how the brain makes sense of speech ... a crowd. // The research suggests that various regions of ... hears, but that when the speech is completely incomprehensible, the ... was intended to simulate the everyday experience of people who ...
Cached Medicine News:Health News:Hydrolysed Casein Formula may Slash Eczema in Infants 2Health News:Making Sense of the World Through a Cochlear Implant 2
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: